TRACON Pharmaceuticals Current Ratio 2013-2021 | TCON

TRACON Pharmaceuticals current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
TRACON Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.02B 1.76
2021-03-31 $0.03B $0.01B 3.04
2020-12-31 $0.04B $0.01B 3.50
2020-09-30 $0.03B $0.01B 2.76
2020-06-30 $0.02B $0.01B 1.62
2020-03-31 $0.02B $0.01B 1.71
2019-12-31 $0.02B $0.01B 1.46
2019-09-30 $0.02B $0.01B 1.58
2019-06-30 $0.03B $0.01B 1.93
2019-03-31 $0.03B $0.01B 2.44
2018-12-31 $0.04B $0.01B 3.01
2018-09-30 $0.05B $0.01B 3.57
2018-06-30 $0.06B $0.01B 4.84
2018-03-31 $0.06B $0.02B 4.23
2017-12-31 $0.04B $0.01B 3.06
2017-09-30 $0.04B $0.01B 3.80
2017-06-30 $0.03B $0.01B 3.57
2017-03-31 $0.04B $0.01B 4.82
2016-12-31 $0.05B $0.01B 4.46
2016-09-30 $0.04B $0.01B 2.77
2016-06-30 $0.04B $0.01B 2.85
2016-03-31 $0.05B $0.01B 3.30
2015-12-31 $0.05B $0.01B 3.76
2015-09-30 $0.06B $0.01B 5.15
2015-06-30 $0.07B $0.01B 6.02
2015-03-31 $0.07B $0.01B 5.23
2014-12-31 $0.04B $0.01B 2.70
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 1.16
2012-12-31 $0.00B $0.00B 3.91
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.068B $0.003B
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86